Compare Heron Therapeutics Inc (HRTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Wells Fargo & Co — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Wells Fargo & Co trades at $82 (market cap $242.71B). The key difference: Wells Fargo & Co is far larger — about 3278.1× Heron Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.49% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Wells Fargo & Co for 87 Days on average.
| HRTX | WFC | |
|---|---|---|
Market Cap | $74.04M | $242.71B |
Volume | 3,668,095 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $1.49 | $96.40 |
52-Week Low | $0.27 | $73.42 |
Typical Hold Time | 35 Days | 87 Days |
Enterprise Value | $180.78M | $498.47B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Wells Fargo (WFC) trades at $82.06, up 0.67% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 25.97% net income margin and 13.13% ROE, trading at attractive valuations (P/E 11.67, P/B 1.47). Recent credit rating upgrade to 'A-' by S&P and stable Fed stress test changes provide positive catalysts, though negative operating cash flow of -$19B in 2025 raises concerns.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (21% upside), supported by improving profitability and stable regulatory environment. Key risks include volatile cash flows, rising interest rate pressures, and execution challenges in maintaining recent momentum. The balanced analyst sentiment (47% Buy, 47% Hold) suggests cautious optimism for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
